Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (ImitrexTM) in Healthy Subjects

Trial Profile

Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (ImitrexTM) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Erenumab (Primary) ; Sumatriptan
  • Indications Angina pectoris; Hot flashes; Migraine
  • Focus Pharmacodynamics
  • Sponsors Amgen
  • Most Recent Events

    • 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
    • 28 Apr 2017 Results assessing effect of sumatriptan alone and in combination with erenumab on resting blood pressure and results of post hoc analysis assessing change in MAP following erenumab and sumatriptan alone, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 09 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top